Comparative Pharmacology
Head-to-head clinical analysis: DEXAMETHASONE ACETATE versus KENALOG H.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEXAMETHASONE ACETATE versus KENALOG H.
DEXAMETHASONE ACETATE vs KENALOG-H
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Agonist at glucocorticoid receptors, modulating gene expression to suppress inflammation, immune response, and adrenal function.
Triamcinolone acetonide is a corticosteroid that binds to the glucocorticoid receptor, leading to inhibition of phospholipase A2, reduced prostaglandin and leukotriene synthesis, and suppression of inflammatory mediators.
0.5-9 mg/day orally in divided doses every 6-12 hours; intravenously or intramuscularly as dexamethasone sodium phosphate; typical anti-inflammatory dose 0.75-9 mg/day. For cerebral edema: IV loading dose 10 mg, then 4 mg every 6 hours. For COVID-19: 6 mg IV or orally once daily for up to 10 days.
2-40 mg (0.1-1 mL) intra-articular, intralesional, or soft tissue injection; intra-articular dose depends on joint size (large joint: 10-40 mg, medium joint: 5-25 mg, small joint: 2-10 mg); repeat every 2-3 weeks as needed.
None Documented
None Documented
Terminal elimination half-life: 3-5 hours in adults; slightly prolonged in neonates (approximately 12-24 hours) and patients with hepatic impairment. Clinical context: Duration of HPA axis suppression may exceed the presence of measurable drug; single dose typically suppresses cortisol for 24-36 hours.
The terminal elimination half-life is approximately 2-3 hours for triamcinolone acetonide. In the context of intra-articular or intralesional administration, the half-life at the site of action is prolonged due to slow release from the injection depot, providing sustained local effects.
Renal (primarily as glucuronide and sulfate conjugates) and biliary/fecal (minor). Approximately 65-80% of a dose is excreted in urine within 24 hours as 20-beta-dihydrodexamethasone (inactive) and conjugated metabolites; about 10-15% appears in feces. Less than 5% is excreted unchanged.
Renal excretion of metabolites (primarily conjugated and unconjugated) accounts for approximately 80-90% of an administered dose, with less than 5% excreted unchanged in urine. Biliary/fecal elimination accounts for the remainder, about 10-20%.
Category D/X
Category C
Corticosteroid
Corticosteroid